Randomized trial · people
Liraglutide: 13.0% vs 14.9% major cardiovascular events in LEADER
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In people with type 2 diabetes and high heart risk, liraglutide lowered the combined rate of heart-related death, heart attack and stroke compared with placebo over a median of 3.8 years.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 9340
- Published
- 2016
- Journal
- N Engl J Med
What they tested
The team tested whether adding liraglutide to usual care in type 2 diabetes was at least as safe for the heart as placebo, and whether it lowered heart events.
How the study was done
A double-blind, randomized, placebo-controlled trial (placebo, a dummy treatment) in 9340 people with type 2 diabetes and high cardiovascular risk, followed for a median of 3.8 years. The main outcome was the first of three events: death from cardiovascular causes, a nonfatal heart attack (myocardial infarction) or a nonfatal stroke.

Model. Individual results vary.
What they found
The main outcome occurred in 608 of 4668 people on liraglutide (13.0%) and 694 of 4672 on placebo (14.9%), a hazard ratio of 0.87 (95% CI 0.78 to 0.97). This met the bar for being no worse than placebo (P<0.001) and also for being better (P=0.01). Cardiovascular death was lower with liraglutide (4.7% vs 6.0%; hazard ratio 0.78), and so was death from any cause (8.2% vs 9.6%; hazard ratio 0.85). Nonfatal heart attack, nonfatal stroke and hospital stays for heart failure were lower with liraglutide, but not significantly, and gastrointestinal events were the most common reason people stopped the drug.
What it doesn’t show
The trial only enrolled people with type 2 diabetes at high cardiovascular risk, and the prespecified exploratory outcomes were not adjusted for testing many outcomes at once. It was funded by Novo Nordisk and the National Institutes of Health.
The paper
Marso et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016.
The compound
More studies on Liraglutide
- Liraglutide: 6.4% weight loss vs 15.8% on semaglutide in STEP 8Randomized trial · people · 2022
- Liraglutide plus exercise: 9.5 kg more loss than placebo at 1 yearRandomized trial · people · 2021
- Liraglutide: 8.4 kg lost vs 2.8 kg on placebo at 56 weeksRandomized trial · people · 2015
- Every study on Liraglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.